EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vitamin K2 Alleviates Insulin Resistance Associated Skeletal Muscle Atrophy via the AKT/mTOR Signalling Pathway

Yingfeng Zhang, Yina Wang, Zhu Ming, Bin Li, Haitao Qi, Hongquan Xie, Guoliang Wang, Jiepeng Chen, Lili Duan, Ran Li, Ying Li iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Yingfeng Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Insulin Resistance, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Muscular Atrophy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Skeletal muscle atrophy and insulin resistance (IR) aggravate each other. Vitamin K2 (VK2) exhibits beneficial effects on IR, but whether it improves IR associated skeletal muscle atrophy remains insufficiently understood. This study aims to investigate the effects of VK2 on IR associated skeletal muscle atrophy in high‐fat diet (HFD) mice and type 2 diabetes mellitus (T2DM) patients and explore the potential mechanisms.

Methods

VK2 was administered to HFD‐fed C57BL/6 mice for 16 weeks. Grip strength, exercise capacity, oral glucose tolerance test (OGTT) and body fat rate were measured. Animals were sacrificed, and skeletal muscle and serum samples were collected to analyse muscle atrophy, glucose and lipid levels. The gene expression profile of skeletal muscle was determined by RNA sequencing. C2C12 cells were cultured for gene knockdown and overexpression experiments. For the randomized controlled trial (RCT), a total of 102 T2DM patients aged 50–80 years were recruited and randomly assigned to receive yogurt (one cup per day) with or without VK2 fortification (90 μg/day) for 6 months. Grip strength, skeletal muscle mass (SM), skeletal muscle mass index (SMI), 6‐m gait speed (6‐m GS), glycated haemoglobin (HbA1c), fasting blood glucose (FBG), fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA‐IR) were measured at 0, 3 and 6 months, respectively.

Results

VK2 significantly improved grip strength ( p < 0.01) and exercise capacity (all p < 0.05) in HFD‐fed mice. At the tissue level, VK2 increased skeletal muscle mass ( p < 0.05) and cross‐sectional area of muscle fibres ( p < 0.05), while reducing the proportion of fast‐twitch fibres ( p < 0.01). VK2 treatment decreased body fat rate ( p < 0.01) accompanied by enhanced whole‐body energy metabolism. VK2 also diminished the glucolipid metabolism parameters, including glucose ( p < 0.01), HOMA‐IR ( p < 0.01) and serum lipid levels. Regarding the mechanism, VK2 promoted the phosphorylation of proteins in the FAK‐AKT–mTOR‐P70S6K pathway by targeting Ccn2, thereby enhancing protein synthesis of C2C12 myotubes. In the RCT study, VK2 supplementation significantly increased grip strength ( p treatment × time = 0.017), SM ( p treatment × time = 0.001), SMI ( p treatment × time < 0.001) and decreased HbA1c ( p treatment × time < 0.001), FBG ( p treatment × time = 0.056), FINS ( p treatment × time < 0.001), and HOMA‐IR ( p treatment × time < 0.001) in T2DM subjects.

Conclusions

Our findings demonstrated the beneficial effects of VK2 on insulin resistance related skeletal muscle atrophy by promoting protein synthesis via the AKT/mTOR pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMuscular AtrophyVitamin K 2AnimalsSignal TransductionMiceHumansMaleMuscle, SkeletalMiddle AgedAgedMice, Inbred C57BLDiabetes Mellitus, Type 2FemaleDiet, High-FatAged, 80 and over

Stichwörter der Autor:innen

AKT/mTOR pathwayinsulin resistancemenaquinone‐7skeletal muscle atrophyvitamin K2

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktVitamin K 2

Autor:innen und Institutionen

  • Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, China.
  • Department of Clinical Nutrition, Zigong First People's Hospital, Zigong, China.
  • Vitamin K2 Research Center, Shenyang Pharmaceutical University, Shenyang, China.

ORCID-Profile: Ying Li

Zitieren

APA

Zhang, Y., Wang, Y., Ming, Z., Li, B., Qi, H., Xie, H., Wang, G., Chen, J., Duan, L., Li, R., & Li, Y. (2025). Vitamin K2 Alleviates Insulin Resistance Associated Skeletal Muscle Atrophy via the AKT/mTOR Signalling Pathway. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13840

Vancouver

Zhang Y, Wang Y, Ming Z, Li B, Qi H, Xie H, et al. Vitamin K2 Alleviates Insulin Resistance Associated Skeletal Muscle Atrophy via the AKT/mTOR Signalling Pathway. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13840

BibTeX
@article{Zhang2025,
  author = {Zhang, Yingfeng and Wang, Yina and Ming, Zhu and Li, Bin and Qi, Haitao and Xie, Hongquan and Wang, Guoliang and Chen, Jiepeng and Duan, Lili and Li, Ran and Li, Ying},
  title = {Vitamin K2 Alleviates Insulin Resistance Associated Skeletal Muscle Atrophy via the AKT/mTOR Signalling Pathway},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13840}
}
Kostenlos starten →